Uploaded October 2026 | Updated November 2026, 3 hours ago
The global health landscape is undergoing profound disruption, while neglected diseases continue to endanger billions of the world’s poor. In response to constrained resources, funders are calling for a transformation of the global health architecture through approaches such as downsizing and mergers. Though these may appear effective, these could undermine the specialized, access-oriented innovation needed to address neglected diseases— areas where incentives are insufficient to drive private sector investment.
Over the past two decades, Product Development Partnerships (PDPs) have contributed to the development and introduction of more than 85 medicines, vaccines, diagnostics, vector control tools, and sexual and reproductive health technologies, benefiting more than 2.4 billion people. These achievements raise important questions about the role PDPs can play within an evolving global health architecture. Key priorities that PDPs operationalize and contribute to include:
• Innovation and comparative advantage: Their Research and Development (R&D) expertise provides a comparative advantage in filling the innovation gap within the changing architecture. Support from donor funding reduces risk and accelerates innovation development.
• Equity, access and country ownership: Working with endemic country leaders in defining products and sustaining gains, PDPs embed access provisions from the outset, ensuring innovations reach populations in need.
• Resilient systems: PDPs contribute to increasing global R&D capacity and strengthening health systems.
• Trusted partnerships: PDPs provide platforms for sustained collaboration across geopolitical and institutional boundaries.
This session will explore the place of PDPs within the evolving global health architecture, highlighting the value of the PDP model in delivering accessible innovations and exploring areas where the model must evolve to respond to the changing realities.
The World Health Summit 2026 takes place October 11–13 in Berlin and online, bringing together leaders and changemakers from science, politics, civil society, and the private sector to address key global health priorities. Learn more at worldhealthsummit.org/.
Chapters:
00:00 Introduction: Shaping Global Health Architecture
01:00 Dirk Müller: How Must Product Development Partnerships Evolve?
05:15 Germany's Perspective: Why Do PDPs Matter for Global Health?
10:00 How Can Partnerships Address Unmet Health Needs?
13:10 Panel 1: The Future of Product Development Partnerships
15:20 Population Council: Can PDPs Consolidate Their Efforts?
19:40 How Can Industry and PDPs Work Together to Fight Malaria?
25:15 Medicines for Malaria Venture: Why Are Partnerships Essential?
29:30 How Can PDPs Secure Sustainable Financing?
32:00 WHO Perspective: Why Must Countries Lead Product Development?
36:00 Audience Q&A: Innovation, Financing, and Local Ownership
40:00 Should PDPs Consolidate as Funding Declines?
44:00 How Can Donors Better Coordinate Research Funding?
48:00 How Can Innovation Reach Communities More Effectively?
53:00 Panel 2: Rethinking PDPs for the Future
55:00 TB Alliance: How Can PDPs Expand Their Funding Base?
61:00 DNDi: How Can Research Capacity Be Sustained in Endemic Countries?
65:00 Bio Farma: How Can Partnerships Strengthen Local Manufacturing?
73:00 IVCC: What Role Should PDPs Play Beyond Product Development?
79:45 Audience Q&A: Are There Too Many PDP Organizations?
85:00 Audience Q&A: How Can PDPs Avoid Duplication?
87:30 Closing Reflections: The Future of PDPs and Global Health Innovation
The global health landscape is undergoing profound disruption, while neglected diseases continue to endanger billions of the world’s poor. In response to constrained resources, funders are calling for a transformation of the global health architecture through approaches such as downsizing and mergers. Though these may appear effective, these could undermine the specialized, access-oriented innovation needed to address neglected diseases— areas where incentives are insufficient to drive private sector investment.
Over the past two decades, Product Development Partnerships (PDPs) have contributed to the development and introduction of more than 85 medicines, vaccines, diagnostics, vector control tools, and sexual and reproductive health technologies, benefiting more than 2.4 billion people. These achievements raise important questions about the role PDPs can play within an evolving global health architecture. Key priorities that PDPs operationalize and contribute to include:
• Innovation and comparative advantage: Their Research and Development (R&D) expertise provides a comparative advantage in filling the innovation gap within the changing architecture. Support from donor funding reduces risk and accelerates innovation development.
• Equity, access and country ownership: Working with endemic country leaders in defining products and sustaining gains, PDPs embed access provisions from the outset, ensuring innovations reach populations in need.
• Resilient systems: PDPs contribute to increasing global R&D capacity and strengthening health systems.
• Trusted partnerships: PDPs provide platforms for sustained collaboration across geopolitical and institutional boundaries.
This session will explore the place of PDPs within the evolving global health architecture, highlighting the value of the PDP model in delivering accessible innovations and exploring areas where the model must evolve to respond to the changing realities.
The World Health Summit 2026 takes place October 11–13 in Berlin and online, bringing together leaders and changemakers from science, politics, civil society, and the private sector to address key global health priorities. Learn more at worldhealthsummit.org/.
Chapters:
00:00 Introduction: Shaping Global Health Architecture
01:00 Dirk Müller: How Must Product Development Partnerships Evolve?
05:15 Germany's Perspective: Why Do PDPs Matter for Global Health?
10:00 How Can Partnerships Address Unmet Health Needs?
13:10 Panel 1: The Future of Product Development Partnerships
15:20 Population Council: Can PDPs Consolidate Their Efforts?
19:40 How Can Industry and PDPs Work Together to Fight Malaria?
25:15 Medicines for Malaria Venture: Why Are Partnerships Essential?
29:30 How Can PDPs Secure Sustainable Financing?
32:00 WHO Perspective: Why Must Countries Lead Product Development?
36:00 Audience Q&A: Innovation, Financing, and Local Ownership
40:00 Should PDPs Consolidate as Funding Declines?
44:00 How Can Donors Better Coordinate Research Funding?
48:00 How Can Innovation Reach Communities More Effectively?
53:00 Panel 2: Rethinking PDPs for the Future
55:00 TB Alliance: How Can PDPs Expand Their Funding Base?
61:00 DNDi: How Can Research Capacity Be Sustained in Endemic Countries?
65:00 Bio Farma: How Can Partnerships Strengthen Local Manufacturing?
73:00 IVCC: What Role Should PDPs Play Beyond Product Development?
79:45 Audience Q&A: Are There Too Many PDP Organizations?
85:00 Audience Q&A: How Can PDPs Avoid Duplication?
87:30 Closing Reflections: The Future of PDPs and Global Health Innovation










